drugset / Trial / NCT00295711

Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain

NCT00295711 ↗

Phase 3 Completed 532 enrolled DOV Pharmaceutical, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of this placebo-controlled clinical trial are to evaluate the analgesic efficacy and safety of bicifadine at three oral dose levels compared with placebo in patients with moderate to severe chronic low back pain. The secondary objectives are to investigate the dose-response relationship of three dose levels of bicifadine, to evaluate the clinical meaningfulness of bicifadine efficacy, to evaluate the effect of bicifadine on function and general quality of life, to describe the population pharmacokinetics of bicifadine in patients with chronic low back pain, and to evaluate safety following discontinuation of bicifadine treatment.

Timeline

Start
2004-09
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicifadine Small molecule 200 mg Oral
Subject Bicifadine Small molecule 300 mg Oral
Subject Bicifadine Small molecule 400 mg Oral

Indications